210 related articles for article (PubMed ID: 30156148)
21. Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations.
Gelder TV; Etsouli O; Moes DJ; Swen JJ
Genes (Basel); 2020 Oct; 11(10):. PubMed ID: 33076474
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.
Iwasaki K
Drug Metab Pharmacokinet; 2007 Oct; 22(5):328-35. PubMed ID: 17965516
[TBL] [Abstract][Full Text] [Related]
23. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.
de Jonge H; de Loor H; Verbeke K; Vanrenterghem Y; Kuypers DR
Clin Pharmacol Ther; 2012 Sep; 92(3):366-75. PubMed ID: 22871995
[TBL] [Abstract][Full Text] [Related]
24. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
Li DY; Teng RC; Zhu HJ; Fang Y
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
[TBL] [Abstract][Full Text] [Related]
25. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
[TBL] [Abstract][Full Text] [Related]
26. Kidney podocyte-associated gene polymorphisms affect tacrolimus concentration in pediatric patients with refractory nephrotic syndrome.
Mo X; Li J; Liu Y; Liao X; Tan M; Chen Y; He F; He Y; Li Y; Huang M
Pharmacogenomics J; 2020 Aug; 20(4):543-552. PubMed ID: 31902946
[TBL] [Abstract][Full Text] [Related]
27. Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome.
Li M; Xu M; Liu W; Gao X
BMC Pharmacol Toxicol; 2018 Apr; 19(1):14. PubMed ID: 29615122
[TBL] [Abstract][Full Text] [Related]
28. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
29. Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions.
Loer HLH; Feick D; Rüdesheim S; Selzer D; Schwab M; Teutonico D; Frechen S; van der Lee M; Moes DJAR; Swen JJ; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):724-738. PubMed ID: 36808892
[TBL] [Abstract][Full Text] [Related]
30. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
[TBL] [Abstract][Full Text] [Related]
31. Diltiazem used as a tacrolimus-sparing agent for treatment of pediatric patients with refractory nephrotic syndrome: a case report and retrospective analysis.
Sun JY; Hu YH; Guo HL; Jing X; Xu ZJ; Sun F; Guo HL; Ding XS; Chen F; Xu J
Eur J Clin Pharmacol; 2019 Apr; 75(4):591-593. PubMed ID: 30483827
[No Abstract] [Full Text] [Related]
32. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
[TBL] [Abstract][Full Text] [Related]
33. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
34. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
[TBL] [Abstract][Full Text] [Related]
35. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome.
Hao GX; Huang X; Zhang DF; Zheng Y; Shi HY; Li Y; Jacqz-Aigrain E; Zhao W
Br J Clin Pharmacol; 2018 Aug; 84(8):1748-1756. PubMed ID: 29637588
[TBL] [Abstract][Full Text] [Related]
37. Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5.
Wang J; Buchman CD; Seetharaman J; Miller DJ; Huber AD; Wu J; Chai SC; Garcia-Maldonado E; Wright WC; Chenge J; Chen T
J Am Chem Soc; 2021 Nov; 143(44):18467-18480. PubMed ID: 34648292
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
Zhao W; Elie V; Roussey G; Brochard K; Niaudet P; Leroy V; Loirat C; Cochat P; Cloarec S; André JL; Garaix F; Bensman A; Fakhoury M; Jacqz-Aigrain E
Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
[TBL] [Abstract][Full Text] [Related]
39. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
[TBL] [Abstract][Full Text] [Related]
40. Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation.
Knops N; Herman J; van Dyck M; Ramazani Y; Debbaut E; van Damme-Lombaerts R; Levtchenko E; van den Heuvel LP; Fieuws S; Kuypers D
Br J Clin Pharmacol; 2017 Apr; 83(4):863-874. PubMed ID: 27966227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
